Patent ductus arteriosus in preterm infants

Indian Pediatrics

Volumn 48, Issue 4, 2011, Pages 301-308

  Sasi, Arun ^a   Deorari, Ashok ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Functional echocardiography; Ibuprofen; Indomethacin; Patent ductus arteriosus; Preterm infant

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DOPAMINE; FUROSEMIDE; IBUPROFEN; INDOMETACIN; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR;

BIRTH WEIGHT; BRAIN HEMORRHAGE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; EARLY DIAGNOSIS; ELECTROCARDIOGRAM; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MORBIDITY; PATENT DUCTUS ARTERIOSUS; PREMATURITY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

BIOLOGICAL MARKERS; CYCLOOXYGENASE INHIBITORS; DUCTUS ARTERIOSUS, PATENT; ECHOCARDIOGRAPHY; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; NATRIURETIC PEPTIDE, BRAIN;

EID: 79958161513     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: 10.1007/s13312-011-0062-5     Document Type: Review

References (37)

1. Shimada S, Kasai T, Konishi M, Fujiwara T. Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant. J Pediatr. 1994;125:270-7.
2. Jegatheesan P, Lanus V, Buchh B, Yoon G BA, Chorne N, Ewig A, et al. Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized controlled trial. J Pediatr. 2008;153:183-9.
3. Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effect of indomethacin in premature infants with patent ductus arteriosus: result of national collaborative study. J Pediatr. 1983;102:895-905.
4. Nemerofsky SL, Parravicini E, Bateman D, Kleinman C, Polin RA, Lorenz JM. The ductus arteriosus rarely requires treatment in infants >1000 grams. Am J Perinatol. 2008;25:661-6.
5. Nemerofsky S, Parravicini E, Kleinman C, et al. The natural course of the ductus arteriosus in very low birthweight infants. E-PAS. 2006;59:542.
6. Rakza T, Magnenant E, Klosowski S, Tourneux P, Bachiri A, Storme L. Early hemodynamic consequences of patent ductus arteriosus in preterm infants with intrauterine growth restriction. J Pedatr. 2007;151:624-8.
7. Dagle JM, Lepp NT, Cooper ME, Schaa KL, Kelsy KJ, Orr KL, et al. Determination of genetic predisposition to patent ductus arteriosus in preterm infants'" Pediatrics. 2009;123:1116-23.
8. Shimada S, Kasai T, Konishi M, Fujiwara T. Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant. J Pediatr. 1994;125:270-7.
9. Clyman R I. Mechanisms regulating the ductus arteriosus. Biol Neonate. 2006; 89:330-5. (Pubitemid 43886949)
10. Evans N, Moorcraft J. Effect of patency of the ductus arteriosus on blood pressure in very preterm infants. Arch Dis Child. 1992;67:1169-73.
11. Lemmers PMA, Toet MC, van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants'" Pediatrics. 2008;121:142-7.
12. Evans N, Malcolm G, Osborn D, Kluckow M. Diagnosis of patent ductus arteriosus in preterm infants. NeoReviews. 2004;5:86-97.
13. Skinner J. Ductal shunting. In Skinner J, Hunter S, Alverson D eds. Echocardiography for the Neonatologist. London: Churchill Livingstone. 2000. p. 151-63.
14. Sehgal A, McNamara PJ. Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus. Eur J Pediatr. 2009;168:907-14.
15. Su BH, Peng CT, Tsai CH. Echocardiographic flow pattern of patent ductus arteriosus: a guide to indomethacin treatment in premature infants. Arch Dis Child Fetal Neonatal Ed. 1999;81:F197-F200.
16. Su BH, Lin HC, Chiu HY,Hsieh HY, Chen HH, Tsai YC. Comparison of ibuprofen and indomethacin for early targeted treatment of patent ductus arteriosus in extremely premature infants a randomized controlled trial. Arch Dis Child Fetal Neonatal. 2008;93:F94-9.
17. Braunwald E. Biomarkers of heart failure. N Engl J Med. 2008;358:2148-59.
18. Koch A, Singer H. Normal values of B-type natriuretic peptide in infants, children and adolescents. Heart. 2003;89:875-8. (Pubitemid 36920810)
19. Choi BM, Lee KH, Eun BL. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics. 2005;115:e255-61.
20. Narayanan-Sankar M, Clyman RI. Pharmacologic closure of patent ductus arteriosus in the neonate. NeoReviews. 2003;4:215-21.
21. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2002;3: CD000174.
22. Cooke L, Steer PA, Woodgate PG. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants Cochrane Database Syst Rev. 2003;1: CD003745.
23. Herrera C, Holberton J, Davis PG. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2007;2:CD003480.
24. Jegatheesan P, Lanus V, Buchh B, Yoon G BA, Chorne N, Ewig A, et al. Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized controlled trial. J Pediatr. 2008;153:183-9.
25. Gork AS, Ehrenkranz RA, Bracken MB. Continuous versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants. Cochrane Database Syst Rev. 2008;1:CD006071.
26. Osborn DA, Evans N, Kluckow M. Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Arch Dis Child Fetal Neonatal Ed. 2003;88:F477-82.
27. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Revs 2010;4:CD003481.
28. Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, De Groote K, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000;343:674-81.
29. Gournay V, Roze MD, Kuster A, Daoud P, Cambonie G, Hascoet JM. Prophylactic ibuprofen versus placebo in very premature infants: a randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:1939-44. (Pubitemid 39574596)
30. Cherif A, Khrouf N, Jabnoun S, Mokrani C, Amara MB, Guellouze N, et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics. 2008;122: e1256-e61.
31. O'Rourke DJ, El-Khuffash A, Moody C, Walsh K, Molloy EJ. Patent ductus arteriosus evaluation by serial echocardiography in preterm infants. Acta Paediatr. 2008;97:574-8.
32. Green TP, Thompson TR, Johnson De, Lock JE. Furosemide promotes patent ductus arteriosus in premature infants with respiratory distress syndrome. N Engl J Med. 1983;308:743-8.
33. Brion LP, Campbell DE. Furosemide for prevention of morbidity in indomethacin treated infants with patent ductus arteriosus. Cochrane Database Syst Rev. 2001;3:CD001148.
34. Barrington KJ, Brion LP. Dopamine versus no treatment to prevent renal dysfunction in indomethacin treated preterm newborn infants. Cochrane Database Syst Rev. 2002;3:CD003213.
35. Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed. 2007;92:F498-F502.
36. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis. J Perinatol. 2010;30:241-52.
37. Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoestenberghe M, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm Arch Dis Child Fetal Neonatal Ed. 2007;92:F244-7.